TSXV:EBM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Eastwood Bio-Medical Canada

Executive Summary

Eastwood Bio-Medical Canada Inc. distributes natural health supplements in North America and Asia. More Details


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has Eastwood Bio-Medical Canada's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EBM is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: EBM's weekly volatility has decreased from 19% to 11% over the past year.


Market Performance


7 Day Return

-7.7%

EBM

16.1%

CA Pharmaceuticals

2.6%

CA Market


1 Year Return

19.3%

EBM

23.2%

CA Pharmaceuticals

0.5%

CA Market

Return vs Industry: EBM underperformed the Canadian Pharmaceuticals industry which returned 23.2% over the past year.

Return vs Market: EBM exceeded the Canadian Market which returned 0.5% over the past year.


Shareholder returns

EBMIndustryMarket
7 Day-7.7%16.1%2.6%
30 Day-8.4%39.0%13.3%
90 Day21.8%35.4%6.0%
1 Year19.3%19.3%23.2%23.2%4.2%0.5%
3 Year2,444.4%2,444.4%-23.4%-24.6%13.0%2.0%
5 Year445.2%445.2%292.9%290.0%49.8%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Eastwood Bio-Medical Canada's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eastwood Bio-Medical Canada undervalued compared to its fair value and its price relative to the market?

214.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EBM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EBM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EBM is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: EBM is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EBM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EBM is overvalued based on its PB Ratio (214.5x) compared to the CA Pharmaceuticals industry average (1.6x).


Next Steps

Future Growth

How is Eastwood Bio-Medical Canada forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

60.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eastwood Bio-Medical Canada has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Eastwood Bio-Medical Canada performed over the past 5 years?

-19.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EBM is currently unprofitable.

Growing Profit Margin: EBM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EBM is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.

Accelerating Growth: Unable to compare EBM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EBM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).


Return on Equity

High ROE: EBM has a negative Return on Equity (-103.86%), as it is currently unprofitable.


Next Steps

Financial Health

How is Eastwood Bio-Medical Canada's financial position?


Financial Position Analysis

Short Term Liabilities: EBM's short term assets (CA$191.5K) do not cover its short term liabilities (CA$225.3K).

Long Term Liabilities: EBM's short term assets (CA$191.5K) exceed its long term liabilities (CA$40.0K).


Debt to Equity History and Analysis

Debt Level: EBM's debt to equity ratio (5.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if EBM's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EBM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: EBM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.3% each year


Next Steps

Dividend

What is Eastwood Bio-Medical Canada current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EBM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EBM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EBM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EBM's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average board tenure


CEO

Youngsoo Kim

0.17

Tenure

Dr. Youngsoo Kim serves as Chief Executive Officer of Eastwood Bio-Medical Canada Inc. since September 2020. He serves as the Chief Executive Officer and Owner of Eastwood Bio-Medical Research Inc. Dr. You...


Board Members

NamePositionTenureCompensationOwnership
Yunji Kim
President8.08yrsCA$36.00kno data
Terrance Owen
Independent Director7.33yrsno datano data
Ian Mallmann
Director1.33yrsCA$7.50kno data
Marcus Kuypers
Independent Director7.33yrsno data0.0058%
CA$ 9.1k

7.3yrs

Average Tenure

62yo

Average Age

Experienced Board: EBM's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Eastwood Bio-Medical Canada Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eastwood Bio-Medical Canada Inc.
  • Ticker: EBM
  • Exchange: TSXV
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$156.371m
  • Shares outstanding: 68.89m
  • Website: https://www.eleotin.ca

Number of Employees


Location

  • Eastwood Bio-Medical Canada Inc.
  • 4871 Shell Road
  • Unit 1130
  • Richmond
  • British Columbia
  • V6X 3Z6
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EBMTSXV (TSX Venture Exchange)YesCommon SharesCACADSep 2014
EWOO.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2014

Biography

Eastwood Bio-Medical Canada Inc. distributes natural health supplements in North America and Asia. The company distributes Eleotin products and related products. Its Eleotin brand of products provides natu...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/28 00:46
End of Day Share Price2020/11/27 00:00
Earnings2020/07/31
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.